LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Regulation FD Disclosure

Lipocine Inc. Exhibit
EX-99.1 2 tv529846_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1   TLANDO (LPCN 1144) Reduces Liver Fat in Men with Fatty Liver   Irwin Goldstein1; Kilyoung Kim2; Somaya Albhaisa3; Jonathan Baker2; Nachiappan Chidambarum2; Arun Sanyal3; Mahesh V. Patel2; Anthony DelConte2,…
To view the full exhibit click here

About LIPOCINE INC. (NASDAQ:LPCN)

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.